Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LEE S SCHWARTZBERG

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1306878228
CMS profile
285831
Location
RENO, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$139,658.26

154 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LEE S SCHWARTZBERG

NPI 1306878228 · CMS profile ID 285831

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

RENO, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1306878228?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LEE S SCHWARTZBERG, NPI 1306878228, CMS profile ID 285831. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1306878228?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). LEE S SCHWARTZBERG, NPI 1306878228, CMS profile ID 285831. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1306878228?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
LEE S SCHWARTZBERG, NPI 1306878228, CMS profile ID 285831, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1306878228?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

154 matching records · $139,658.26 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 154 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 154.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Daiichi Sankyo Inc. $10.9205/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089480049 CMS
Novartis Pharmaceuticals Corporation $83.3305/16/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087156397 CMS
AstraZeneca Pharmaceuticals LP $675.0005/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105851644 CMS
Ipsen Biopharmaceuticals, Inc $24.7505/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091980695 CMS
Merck Sharp & Dohme LLC $579.2805/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141635331 CMS
Merck Sharp & Dohme LLC $184.6705/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141635333 CMS
Merck Sharp & Dohme LLC $460.8205/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141635335 CMS
Merck Sharp & Dohme LLC $105.3105/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141635337 CMS
Lilly USA, LLC $15.6805/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135138478 CMS
PFIZER INC. $18.0905/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131331072 CMS
PFIZER INC. $1.8205/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131331076 CMS
AstraZeneca Pharmaceuticals LP $5,500.0004/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104391433 CMS
Napo Pharmaceuticals Inc $3,000.0004/21/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148207621 CMS
Janssen Biotech, Inc. $28.5104/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078398201 CMS
Novartis Pharmaceuticals Corporation $82.1904/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087156381 CMS
Novartis Pharmaceuticals Corporation $83.3304/18/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087156395 CMS
PFIZER INC. $30.3104/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131311239 CMS
Cornerstone Specialty Network LLC $650.0004/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154766968 CMS
Cornerstone Specialty Network LLC $871.0004/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154766970 CMS
Cornerstone Specialty Network LLC $541.0004/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154766972 CMS
AstraZeneca Pharmaceuticals LP $297.0204/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104748031 CMS
AstraZeneca Pharmaceuticals LP $128.7704/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105576046 CMS
AstraZeneca Pharmaceuticals LP $335.0404/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105662048 CMS
Daiichi Sankyo Inc. $4.7004/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089480047 CMS
SOBI, INC $48.2604/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141408990 CMS
Daiichi Sankyo Inc. $650.0004/07/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089480035 CMS
Daiichi Sankyo Inc. $2,600.0004/07/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089480037 CMS
AstraZeneca Pharmaceuticals LP $16.2104/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105269528 CMS
ARRAY BIOPHARMA INC $19.7603/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131294685 CMS
Novartis Pharmaceuticals Corporation $83.3303/15/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087156393 CMS
AstraZeneca Pharmaceuticals LP $5,500.0003/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104560268 CMS
AstraZeneca Pharmaceuticals LP $121.8202/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104760822 CMS
AstraZeneca Pharmaceuticals LP $333.6702/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105576800 CMS
Cornerstone Specialty Network LLC $2,055.0002/26/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126532565 CMS
Daiichi Sankyo Inc. $5,200.0002/25/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089480033 CMS
Daiichi Sankyo Inc. $1,950.0002/25/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089480039 CMS
Cornerstone Specialty Network LLC $500.0002/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126532647 CMS
Cornerstone Specialty Network LLC $634.0002/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126532649 CMS
Cornerstone Specialty Network LLC $110.0002/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126532651 CMS
Novartis Pharmaceuticals Corporation $83.3302/16/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087156391 CMS
AstraZeneca Pharmaceuticals LP $1,350.0002/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104763164 CMS
Daiichi Sankyo Inc. $154.4602/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089480071 CMS
Daiichi Sankyo Inc. $193.0002/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089480069 CMS
Daiichi Sankyo Inc. $65.2101/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089480045 CMS
AstraZeneca Pharmaceuticals LP $2,750.0001/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105783588 CMS
Novartis Pharmaceuticals Corporation $83.3301/18/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087156389 CMS
AstraZeneca Pharmaceuticals LP $5,500.0001/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104304368 CMS
AstraZeneca Pharmaceuticals LP $111.1301/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105532208 CMS
Cornerstone Specialty Network LLC $5.0001/15/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126532563 CMS
Napo Pharmaceuticals Inc $3,000.0001/10/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148207619 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $71,430.56 92
PY2020 $68,589.82 37
PY2021 $141,989.46 69
PY2022 $139,755.62 94
PY2023 $111,993.78 85
PY2024 $139,658.26 154
PY2025 $137,102.33 116

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $125.00 1
PY2025 Principal investigator $1,198,519.86 77
PY2024 Recipient $11,678.86 5
PY2024 Principal investigator $1,036,057.75 78
PY2023 Recipient $9,937.71 1
PY2023 Principal investigator $349,635.90 29
PY2022 Recipient $3,195.65 5
PY2022 Principal investigator $209,745.03 11
PY2021 Recipient $11,105.61 9
PY2021 Principal investigator $1,170,134.05 40
PY2020 Recipient $11,505.17 11
PY2020 Principal investigator $1,710,287.78 70
PY2019 Recipient $21,967.49 5
PY2019 Principal investigator $182,904.88 62

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

78 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $86,640.20 12/31/2025 Covered Recipient Teaching Hospital
Renown Regional Medical Center
A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan sac-TMT, MK-2870 as a Monotherapy and in Combination with PembrolizumabMK-3475 Versus Treatment of Physician's Choice in Participants With Previously Untr No dispute reported 06/30/2026 1232923122
Principal investigator 1 Merck Sharp & Dohme LLC $60,253.28 12/31/2025 Covered Recipient Teaching Hospital
Renown Regional Medical Center
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT Sacituzumab Tirumotecan, MK-2870 Followed by Carboplatin,Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Earl No dispute reported 06/30/2026 1232925115
Principal investigator 1 Merck Sharp & Dohme LLC $28,009.77 12/31/2025 Covered Recipient Teaching Hospital
Renown Regional Medical Center
A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastatic Breast Cancer After Progression on Previous E No dispute reported 06/30/2026 1232934764
Principal investigator 1 PFIZER INC. $6,568.80 12/31/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228733615
Principal investigator 1 PFIZER INC. $3,154.20 12/29/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228716759
Principal investigator 1 PFIZER INC. $18,384.10 12/27/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228725276
Principal investigator 1 Merck Sharp & Dohme LLC $85,728.00 12/15/2025 Covered Recipient Teaching Hospital
Renown Regional Medical Center
A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastatic Breast Cancer After Progression on Previous E No dispute reported 06/30/2026 1232934762
Principal investigator 1 PFIZER INC. $2,189.60 12/13/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228746985
Principal investigator 1 PFIZER INC. $2,102.80 12/09/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228716757
Recipient Hoffmann-La Roche Limited $125.00 12/08/2025 Covered Recipient Physician MORPHEUS TNBC No dispute reported 06/30/2026 1211537348
Principal investigator 1 PFIZER INC. $76,400.80 12/04/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228711940
Principal investigator 1 PFIZER INC. $37.50 12/04/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228712008
Principal investigator 1 PFIZER INC. $27,059.90 11/26/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228726832
Principal investigator 1 PFIZER INC. $2,102.80 11/04/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228716933
Principal investigator 1 PFIZER INC. $7,617.40 10/31/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228730649
Principal investigator 1 Novartis Pharmaceuticals Corporation $42,691.19 10/28/2025 Covered Recipient Teaching Hospital
Renown Regional Medical Center
A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) No dispute reported 06/30/2026 1190297816
Principal investigator 1 PFIZER INC. $30.00 10/17/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228712126
Principal investigator 1 PFIZER INC. $468.45 10/14/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228712520
Principal investigator 1 PFIZER INC. $2,102.80 10/13/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228716663
Principal investigator 1 PFIZER INC. $4,697.00 10/09/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228742026
Principal investigator 1 PFIZER INC. $3,556.00 09/24/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228758438
Principal investigator 1 PFIZER INC. $22.50 09/18/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228711942
Principal investigator 1 PFIZER INC. $57,300.60 09/18/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228712128
Principal investigator 1 PFIZER INC. $95,501.00 09/09/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228711826
Principal investigator 1 PFIZER INC. $30.00 09/09/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228712006
Principal investigator 1 PFIZER INC. $9,940.00 09/09/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228749587
Principal investigator 1 PFIZER INC. $2,102.80 09/04/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228716841
Principal investigator 1 PFIZER INC. $6,950.30 08/29/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228787738
Principal investigator 1 Genentech, Inc. $900.00 08/26/2025 Covered Recipient Teaching Hospital
Renown Regional Medical Center
Efficacy and Safety of Inavolisib Phesgo vs Placebo Phesgo in PIK3CA Mutated HER2 BC No dispute reported 06/30/2026 1211553217
Principal investigator 1 Genentech, Inc. $350.00 08/21/2025 Covered Recipient Teaching Hospital
Renown Regional Medical Center
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211553330
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $10,250.00 08/14/2025 Covered Recipient Teaching Hospital
Renown Regional Medical Center
A phase I open-label, dose-escalation and cohort expansion study of LUNA18 monotherapy and combination therapy in patients with locally advanced or metastatic solid tumors No dispute reported 06/30/2026 1211553233
Principal investigator 1 PFIZER INC. $114,601.20 08/12/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228711888
Principal investigator 1 PFIZER INC. $30,560.30 08/12/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228712326
Principal investigator 1 PFIZER INC. $15.00 08/12/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228712518
Principal investigator 1 PFIZER INC. $1,048.60 08/08/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228767387
Principal investigator 1 PFIZER INC. $2,102.80 08/04/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228717619
Principal investigator 1 PFIZER INC. $22.50 08/01/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228712392
Principal investigator 1 PFIZER INC. $52,240.30 07/31/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228789566
Principal investigator 1 PFIZER INC. $7,030.80 07/16/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228783864
Principal investigator 1 PFIZER INC. $2,102.80 07/09/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228716661
Principal investigator 1 PFIZER INC. $15.00 07/01/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228711824
Principal investigator 1 PFIZER INC. $2,102.80 06/04/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228717621
Principal investigator 1 PFIZER INC. $2,102.80 06/04/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228754376
Principal investigator 1 PFIZER INC. $22.50 05/30/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228762552
Principal investigator 1 PFIZER INC. $16,649.30 05/30/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228773258
Principal investigator 1 PFIZER INC. $5,560.80 05/29/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228771976
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $850.00 05/28/2025 Covered Recipient Teaching Hospital
Renown Regional Medical Center
A phase I open-label, dose-escalation and cohort expansion study of LUNA18 monotherapy and combination therapy in patients with locally advanced or metastatic solid tumors No dispute reported 06/30/2026 1211553229
Principal investigator 1 Genentech, Inc. $1,200.00 05/20/2025 Covered Recipient Teaching Hospital
Renown Regional Medical Center
Efficacy and Safety of Inavolisib Phesgo vs Placebo Phesgo in PIK3CA Mutated HER2 BC No dispute reported 06/30/2026 1211553210
Principal investigator 1 PFIZER INC. $10,940.00 05/13/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228755416
Principal investigator 1 PFIZER INC. $43,996.68 05/13/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228758753
Principal investigator 1 PFIZER INC. $43,996.68 05/12/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228757179
Principal investigator 1 PFIZER INC. $10,940.00 05/12/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228759529
Principal investigator 1 PFIZER INC. $1,822.00 05/12/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER No dispute reported 06/30/2026 1228771854
Principal investigator 1 PFIZER INC. $15.00 05/02/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228720505
Principal investigator 1 Genentech, Inc. $248.00 04/28/2025 Covered Recipient Teaching Hospital
Renown Regional Medical Center
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211553293
Principal investigator 1 PFIZER INC. $3,154.20 04/28/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228716843
Principal investigator 1 PFIZER INC. $3,154.20 04/28/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228758763
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $2,963.00 04/21/2025 Covered Recipient Teaching Hospital
Renown Regional Medical Center
A phase I open-label, dose-escalation and cohort expansion study of LUNA18 monotherapy and combination therapy in patients with locally advanced or metastatic solid tumors No dispute reported 06/30/2026 1211553221
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $8,431.91 04/21/2025 Covered Recipient Teaching Hospital
Renown Regional Medical Center
A phase I open-label, dose-escalation and cohort expansion study of LUNA18 monotherapy and combination therapy in patients with locally advanced or metastatic solid tumors No dispute reported 06/30/2026 1211553225
Principal investigator 1 PFIZER INC. $4,082.52 04/09/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228760638
Principal investigator 1 PFIZER INC. $15.00 04/09/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228761687
Principal investigator 1 PFIZER INC. $57,300.60 04/09/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228762547
Principal investigator 1 PFIZER INC. $15,280.15 04/09/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228768300
Principal investigator 1 PFIZER INC. $12,247.56 04/09/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228768306
Principal investigator 1 Genentech, Inc. $466.00 04/07/2025 Covered Recipient Teaching Hospital
Renown Regional Medical Center
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211553267
Principal investigator 1 Genentech, Inc. $249.00 04/07/2025 Covered Recipient Teaching Hospital
Renown Regional Medical Center
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211553277
Principal investigator 1 Genentech, Inc. $2,367.00 04/07/2025 Covered Recipient Teaching Hospital
Renown Regional Medical Center
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211553284
Principal investigator 1 Genentech, Inc. $4,500.00 04/01/2025 Covered Recipient Teaching Hospital
Renown Regional Medical Center
RO7247669 PLUS PLATINUM BASED CX VERSUS PEMBROLIZUMAB PLUS PLATINUM BASED CX IN 1L NSCLC Ph2 No dispute reported 06/30/2026 1211553318
Principal investigator 1 Novartis Pharmaceuticals Corporation $44,325.32 03/24/2025 Covered Recipient Teaching Hospital
Renown Regional Medical Center
A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) No dispute reported 06/30/2026 1190295351
Principal investigator 1 Genentech, Inc. $500.00 03/20/2025 Covered Recipient Teaching Hospital
Renown Regional Medical Center
Efficacy and Safety of Inavolisib Phesgo vs Placebo Phesgo in PIK3CA Mutated HER2 BC No dispute reported 06/30/2026 1211553213
Principal investigator 1 PFIZER INC. $2,000.00 03/04/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228779569
Principal investigator 1 PFIZER INC. $1,728.00 03/03/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228797830
Principal investigator 1 Genentech, Inc. $95.00 02/25/2025 Covered Recipient Teaching Hospital
Renown Regional Medical Center
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211553270
Principal investigator 1 Genentech, Inc. $850.00 02/25/2025 Covered Recipient Teaching Hospital
Renown Regional Medical Center
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211553289
Principal investigator 1 Genentech, Inc. $350.00 02/18/2025 Covered Recipient Teaching Hospital
Renown Regional Medical Center
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211553281
Principal investigator 1 PFIZER INC. $23,036.00 02/05/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 No dispute reported 06/30/2026 1228759080
Principal investigator 1 PFIZER INC. $17,934.75 02/03/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 IHC 1 AND GREATER No dispute reported 06/30/2026 1228795484
Principal investigator 1 PFIZER INC. $162.00 01/06/2025 Covered Recipient Teaching Hospital
RENOWN REGIONAL MEDICAL CENTER
A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS No dispute reported 06/30/2026 1228723542

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2025 Amount invested $0.00 1
PY2025 Value of interest $50,000.00 1
PY2024 Amount invested $0.00 1
PY2024 Value of interest $50,000.00 1
PY2023 Amount invested $50,000.00 1
PY2023 Value of interest $50,000.00 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

3 records · PY2023–2025

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2025 Cornerstone Specialty Network LLC $0.00 $50,000.00 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1176816272
PY2024 Cornerstone Specialty Network LLC $0.00 $50,000.00 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1126328727
PY2023 Cornerstone Specialty Network LLC $50,000.00 $50,000.00 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 987500409